UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

 

FORM 10-Q

 

(Mark One)

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended SeptemberJune 30, 20212022

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____________ to _____________

 

Commission file number: 000-28827

______________________

 

PETMED EXPRESS, INC.

(Exact name of registrant as specified in its charter)

______________________

 

Floridaflorida

65-0680967

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

420 South Congress Avenue, Delray Beach, Florida 33445

(Address of principal executive offices, including zip code)

 

(561) 526-4444

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Exchange Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $.001 per share

PETS

NASDAQ Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 20,942,92921,013,848 Common Shares, $.001 par value per share at NovemberAugust 2, 2021.2022.

 

 

 

 

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

 

PETMED EXPRESS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except for per share amounts)

 

 

September 30,

 

March 31,

  

June 30,

 

March 31,

 
 

2021

  

2021

  

2022

  

2022

 
 

(Unaudited)

     

(Unaudited)

    

ASSETS

         
  

Current assets:

  

Cash and cash equivalents

 $106,562  $118,718  $105,414  $111,080 

Accounts receivable, less allowance for doubtful accounts of $28 and $39, respectively

 1,854  2,587 

Inventories - finished goods, net

 19,733  34,420 

Accounts receivable, less allowance for doubtful accounts of $36 and $39, respectively

 1,782  1,913 

Inventories - finished goods

 22,575  32,455 

Prepaid expenses and other current assets

 4,397  4,503  4,415  4,866 

Prepaid income taxes

  899   959   0   681 

Total current assets

 133,445  161,187  134,186  150,995 
  

Noncurrent assets:

  

Property and equipment, net

 25,081  25,450  24,693  24,464 

Minority interest investment in Vetster

 5,000  0 

Intangible assets

  860   860   860   860 

Total noncurrent assets

  25,941   26,310   30,553   25,324 
  

Total assets

 $159,386  $187,497  $164,739  $176,319 
  

LIABILITIES AND SHAREHOLDERS' EQUITY

                
  

Current liabilities:

  

Accounts payable

 $11,183  $39,548  $17,031  $27,500 

Accrued expenses and other current liabilities

  5,089   5,387  6,027  5,697 

Income taxes payable

  839   0 

Total current liabilities

 16,272  44,935  23,897  33,197 
  

Deferred tax liabilities

  1,627   1,281   642   936 
  

Total liabilities

  17,899   46,216   24,539   34,133 
  

Commitments and contingencies

          
  

Shareholders' equity:

  

Preferred stock, $.001 par value, 5,000 shares authorized; 3 convertible shares issued and outstanding with a liquidation preference of $4 per share

 9  9 

Common stock, $.001 par value, 40,000 shares authorized; 20,943 and 20,269 shares issued and outstanding, respectively

 21  20 

Preferred stock, $.001 par value, 5,000 shares authorized; 3 convertible shares issued and outstanding with a liquidation preference of $4 per share

 9  9 

Common stock, $.001 par value, 40,000 shares authorized; 20,989 and 20,979 shares issued and outstanding, respectively

 21  21 

Additional paid-in capital

 8,711  7,111  13,196  11,660 

Retained earnings

  132,746   134,141   126,974   130,496 
  

Total shareholders' equity

  141,487   141,281   140,200   142,186 
  

Total liabilities and shareholders' equity

 $159,386  $187,497  $164,739  $176,319 

 

See accompanying notes to condensed consolidated financial statements.

 

1

 

 

PETMED EXPRESS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except for per share amounts) (Unaudited)

 

 

Three Months Ended

 

Six Months Ended

  

Three Months Ended

 
 

September 30,

 

September 30,

  

June 30,

 
 

2021

  

2020

  

2021

  

2020

  

2022

  

2021

 
  

Sales

 $67,386  $75,436  $146,698  $171,640  $70,187  $79,312 

Cost of sales

  48,212   52,418   105,744   121,837   50,244   57,532 
  

Gross profit

  19,174   23,018   40,954   49,803   19,943   21,780 
  

Operating expenses:

  

General and administrative

 6,958  6,809  14,999  14,563  9,351  8,041 

Advertising

 3,435  5,131  11,108  14,164  6,349  7,673 

Depreciation

  694   607   1,341   1,169   753   647 

Total operating expenses

  11,087   12,547   27,448   29,896   16,453   16,361 
  

Income from operations

  8,087   10,471   13,506   19,907   3,490   5,419 
  

Other income:

  

Interest income, net

 74  66  159  156  117  85 

Other, net

  170   338   454   593   198   284 

Total other income

  244   404   613   749   315   369 
  

Income before provision for income taxes

 8,331  10,875  14,119  20,656  3,805  5,788 
  

Provision for income taxes

  1,982   2,463   3,342   4,476   1,030   1,360 
  

Net income

 $6,349  $8,412  $10,777  $16,180  $2,775  $4,428 
  

Net income per common share:

  

Basic

 $0.31  $0.42  $0.53  $0.81  $0.14  $0.22 

Diluted

 $0.31  $0.42  $0.53  $0.81  $0.14  $0.22 
  

Weighted average number of common shares outstanding:

Weighted average number of common shares outstanding:

        

Basic

  20,178   20,063   20,144   20,024   20,208   20,109 

Diluted

  20,568   20,154   20,384   20,098   20,291   20,200 
  

Cash dividends declared per common share

 $0.30  $0.28  $0.60  $0.56  $0.30  $0.30 

 

See accompanying notes to condensed consolidated financial statements.

 

2


 

 

PETMED EXPRESS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands) (Unaudited)

 

 

Six Months Ended

  

Three Months Ended

 
 

September 30,

  

June 30,

 
 

2021

  

2020

  

2022

  

2021

 

Cash flows from operating activities:

  

Net income

 $10,777  $16,180  $2,775  $4,428 

Adjustments to reconcile net income to net cash provided by operating activities:

  

Depreciation

 1,341  1,169  753  647 

Share based compensation

 1,600  1,513  1,536  718 

Deferred income taxes

 346  408  (294) (167)

Bad debt expense

 58  61  45  29 

(Increase) decrease in operating assets and increase (decrease) in liabilities:

  

Accounts receivable

 675  1,570  86  396 

Inventories - finished goods

 14,687  (3,567) 9,880  5,246 

Prepaid income taxes

 60  0  681  959 

Prepaid expenses and other current assets

 106  916  451  442 

Accounts payable

 (28,365) (3,600) (10,469) (14,834)

Accrued expenses and other current liabilities

 (210) 391  97  1,145 

Income taxes payable

  0   147   839   569 

Net cash provided by operating activities

  1,075   15,188 

Net cash provided by (used in) operating activities

  6,380   (422)
  

Cash flows from investing activities:

  

Purchase of minority interest investment in Vetster

 (5,000) 0 

Purchases of property and equipment

  (972)  (1,193)  (982)  (477)

Net cash used in investing activities

  (972)  (1,193)  (5,982)  (477)
  

Cash flows from financing activities:

  

Dividends paid

  (12,259)  (11,413)  (6,064)  (6,033)

Net cash used in financing activities

  (12,259)  (11,413)  (6,064)  (6,033)
  

Net (decrease) increase in cash and cash equivalents

 (12,156) 2,582 

Net decrease in cash and cash equivalents

 (5,666) (6,932)

Cash and cash equivalents, at beginning of period

  118,718   103,762   111,080   118,718 
  

Cash and cash equivalents, at end of period

 $106,562  $106,344  $105,414  $111,786 
  

Supplemental disclosure of cash flow information:

  
  

Cash paid for income taxes

 $2,935  $4,206 
 

Dividends payable in accrued expenses

 $110  $126  $791  $245 

 

See accompanying notes to condensed consolidated financial statements.

 

3


 

PETMED EXPRESS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

 

 

Note 1:  Summary of Significant Accounting Policies

 

Organization

 

PetMed Express, Inc. and subsidiaries, d/b/a PetMedsPetMeds® (the “Company”), is a leading nationwide pet pharmacy.pharmacy and Your Trusted Pet Health ExpertTM. The Company markets prescription and non-prescription pet medications, health products, and supplies for dogs, cats, and horses, directdirectly to the consumer. The Company offers consumers an attractive alternative for obtaining pet medications in terms of convenience, price, speed of delivery and valued customer service. The Company markets its products through national advertising and promotional campaigns, which aim to increase the recognition of the “PetMeds”“PetMeds®” brand name, increase traffic on its website at www.petmeds.com, acquire new customers, and maximize repeat purchases. Virtually all of the Company’s sales are to residentscustomers in the United States. The Company’s corporate headquarters and distribution facility is located in Delray Beach, Florida. The Company’s fiscal year end is March 31, and references herein to fiscal 20222023 or fiscal 20212022 refer to the Company's fiscal years ending March 31, 2022 2023 and 2021,2022, respectively.

 

Basis of Presentation and Consolidation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with the instructions to Form 10-Q10-Q and, therefore, do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, the accompanying Condensed Consolidated Financial Statements contain all adjustments, consisting of normal recurring accruals, necessary to present fairly the financial position of the Company at SeptemberJune 30, 2021, 2022, the Statements of Income for the three and six months ended SeptemberJune 30, 2021 2022 and 2020,2021, and Cash Flows for the sixthree months ended SeptemberJune 30, 2021 2022 and 2020.2021. The results of operations for the three and six months ended SeptemberJune 30, 2021 2022 are not necessarily indicative of the operating results expected for the fiscal year ending March 31, 2022. 2023. These financial statements should be read in conjunction with the financial statements and notes thereto contained in the Company’s annual report on Form 10-K10-K for the fiscal year ended March 31, 2021. 2022. The Condensed Consolidated Financial Statements include the accounts of PetMed Express, Inc. and its wholly owned subsidiaries. All significant intercompany transactions have been eliminated upon consolidation.

 

Use of Estimates

 

The preparation of Condensed Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Fair Value of Financial Instruments

 

The carrying amounts of the Company's cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to the short-term nature of these instruments.

 

Recent Accounting Pronouncements

In March 2020, the Financial Accounting Standards Board issued ASU 2020-03, “Codification Improvements to Financial Instruments” (“ASU 2020-03”). ASU 2020-03 improves and clarifies various financial instruments topics. ASU 2020-03 includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The Company will adopt ASU 2020-03 on April 1, 2022. The Company does not expect the adoption of this new standard to have a material impact on our consolidated financial statements.

 

The Company does not believe that any other recently issued, but not yet effective, accounting standards, if currently adopted, will have a material effect on the Company’sCompany's consolidated financial position, results of operations, or cash flows.

 

4

 

Note 2:  Revenue Recognition

 

The Company generates revenue by selling pet medication products and pet supplies mainly to retail customers. Certain pet supplies offered on the Company’s website are drop shipped to customers. The Company considers itself the principal in the arrangement because the Company controls the specified good before it is transferred to the customer. Revenue contracts contain one performance obligation, which is delivery of the product; customer care and support is deemed not to be a material right into the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are estimated based on historical patterns, however this is not considered a key judgment. There are no amounts excluded from the variable consideration. Revenue is recognized when control transfers to the customer at the point in time in which the shipment of the product occurs. This key judgment is determined as the shipping point, which represents the point in time in whichwhen the Company has a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership.

 

Outbound shipping and handling fees are an accounting policy election and are included in sales as the Company considers itself the principal in the arrangement given its responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales.

 

The Company disaggregates revenue in the following two categories: (1) Reorder(1) reorder revenue vs new order revenue, and (2) Internet(2) internet revenue vs. contact center revenue. The following table illustrates revenue by various classifications:

 

Three Months Ended September 30,

 

Sales (In thousands)

 

2021

  

%

  

2020

  

%

  

$ Variance

  

% Variance

 
                         

Reorder Sales

 $62,016   92.0% $67,761   89.8% $(5,745)  -8.5%

New Order Sales

  5,370   8.0%  7,675   10.2%  (2,305)  -30.0%
                         

Total Net Sales

 $67,386   100.0% $75,436   100.0% $(8,050)  -10.7%
                         

Internet Sales

 $55,961   83.0% $62,697   83.1% $(6,736)  -10.7%

Contact Center Sales

  11,425   17.0%  12,739   16.9%  (1,314)  -10.3%
                         

Total Net Sales

 $67,386   100.0% $75,436   100.0% $(8,050)  -10.7%

Six Months Ended September 30,

 

Sales (In thousands)

 

2021

  

%

  

2020

  

%

  

$ Variance

  

% Variance

 

Three Months Ended June 30,

Three Months Ended June 30,

 

Revenue (In thousands)

 

2022

  

%

  

2021

  

%

  

$ Variance

  

% Variance

 
  

Reorder Sales

 $132,953  90.6% $148,186  86.3% $(15,233) -10.3% $63,339  90.2% $70,937  89.4% $(7,598) -10.7%

New Order Sales

  13,745   9.4%  23,454   13.7%  (9,709)  -41.4%  6,848   9.8%  8,375   10.6%  (1,527)  -18.2%
  

Total Net Sales

 $146,698   100.0% $171,640   100.0% $(24,942)  -14.5% $70,187   100.0% $79,312   100.0% $(9,125)  -11.5%
  

Internet Sales

 $122,408  83.4% $144,208  84.0% $(21,800) -15.1% $60,295  85.9% $66,447  83.8% $(6,152) -9.3%

Contact Center Sales

  24,290   16.6%  27,432   16.0%  (3,142)  -11.5%  9,892   14.1%  12,865   16.2%  (2,973)  -23.1%
  

Total Net Sales

 $146,698   100.0% $171,640   100.0% $(24,942)  -14.5% $70,187   100.0% $79,312   100.0% $(9,125)  -11.5%

 

The Company changed the definition of a new customer on April 1, 2022, to include anyone who has not ordered over the past thirty-six months. The reorder and new order sales amounts for three months ended June 30, 2022 reflect this change in the new customer definition. The reorder and new order sales for the three months ended June 30, 2021 do not reflect this new customer definition. Had the Company changed the definition of a new customer in the prior year, reorder sales for the three months ended June 30, 2021 would have been $68.7 million instead of $70.9 million reported above, and new order sales would have been $10.6 million instead of $8.4 million reported above. Virtually all of the Company’s sales are paid by credit cards and the Company usually receives the cash settlement in two to three banking days. Credit card sales minimize the accounts receivable balances relative to sales. The Company had no material contract asset or contract liability balances as of SeptemberJune 30, 2021 2022 or March 31, 2021.2022.

 

5

 

Note 3:  Net Income Per Share

 

In accordance with the provisions of Accounting Standards Codification (ASC)(“ASC”) Topic 260 (“Earnings Per Share”) basic net income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per common share includes the dilutive effect of potential restricted stock and the effects of the potential conversion of preferred shares, calculated using the treasury stock method. Unvested restricted stock and convertible preferred shares issued by the Company represent the only dilutive effect reflected in the diluted weighted average shares outstanding.

5

The following is a reconciliation of the numerators and denominators of the basic and diluted net income per share computations for the periods presented (in thousands, except for per share amounts):

 

 

Three Months Ended

September 30,

 

Six Months Ended

September 30,

  

Three Months Ended June 30,

 
 

2021

  

2020

  

2021

  

2020

  

2022

  

2021

 

Net income (numerator):

          

Net income

 $6,349  $8,412  $10,777  $16,180  $2,775  $4,428 
 

Shares (denominator):

          
 

Weighted average number of common shares outstanding used in basic computation

 20,178  20,063  20,144  20,024  20,208  20,109 

Common shares issuable upon vesting of restricted stock

 380  81  230  64  73  81 

Common shares issuable upon conversion of preferred shares

  10   10   10   10   10   10 

Shares used in diluted computation

  20,568   20,154   20,384   20,098   20,291   20,200 
 

Net income per common share:

          
 

Basic

 $0.31  $0.42  $0.53  $0.81  $0.14  $0.22 

Diluted

 $0.31  $0.42  $0.53  $0.81  $0.14  $0.22 

 

For the three and six months ended SeptemberJune 30, 2022 and 2021, 115,219251,192 and 22,248 shares of common restricted stock, were excluded from the computations of diluted net income per common share, as their inclusion would have had an anti-dilutive effect on diluted net income per common share. For the three and six months ended September 30, 2020, 25,136 shares of common restricted stockrespectively, were excluded from the computations of diluted net income per common share, as their inclusion would have had an anti-dilutive effect on diluted net income per common share.

 

 

Note 4:  Accounting for Stock-Based Compensation

 

The Company records compensation expense associated with restricted stock in accordance with ASC Topic 718 (“Share Based Payment”) (ASU 2016-09)2016-09). The compensation expense related to all of the Company’s stock-based compensation arrangements is recorded as a component of general and administrative expenses. The Company had 861,275901,358 restricted common shares issued under the 2016 Employee Equity Compensation Restricted Stock Plan ((“2016 Employee Plan”), and 203,880210,755 restricted common shares issued under the 2015 Outside Director Equity Compensation Restricted Stock Plan ((“2015 Director Plan”) at SeptemberJune 30, 2021, 2022, all shares of which were issued subject to a restriction or forfeiture period that lapses ratably on the first, second, and third anniversaries of the date of grant, and the fair value of which is being amortized over the threeone-year to three-year restriction period.

 

In July 2021, theThe Company issued 41,74510,125 shares of restricted stock during the quarter ended June 30, 2022 and 1,380 shares to certain employees ofduring the Company under the 2016 Employee Plan, with a fair value of $31.39 per share. In August 2021, the Company issued 90,000 restricted shares and 510,000 performance restricted shares to the Company’s CEO, in accordance with the CEO’s employment agreement, under the 2016 Employee Plan. The fair value of the 90,000 restricted shares issuance was valued at $28.70 per share. The value of the 510,000 performance restricted shares issuance was valued by a third party valuation firm, and these shares were valued at $9.7 million, or $19.06 per share. The valuation firm utilized a Monte Carlo model to value the 510,000 performance restricted shares and looked at several other factors such as historical stock price volatility. In July 2021, the Company issued 37,500 restricted shares to directors of the Company under the 2015 Director Plan, with a fair value of $31.39 per share. In September 2021, the Company issued 1,350 restricted shares to a certain employee of the Company under the 2016 Employee Plan, with a fair value of $26.87 per share.

6

quarter ended June 30, 2021. For the quarters ended SeptemberJune 30, 2021 2022 and 2020,2021, the Company recognized $882,000$1.5 million and $772,000,$718,000, respectively, of compensation expense related to the 2016 Employee Plan and 2015 Director Plans. For the six months ended SeptemberPlan. At June 30, 2022 and 2021 and 2020, the Company recognized $1.6there was $12.3 million and $1.5 million, respectively, of compensation expense related to the 2016 Employee and 2015 Director Plans. At September 30, 2021 and 2020, there was $15.8 million and $4.4$1.9 million of unrecognized compensation cost related to the non-vested restricted stock awards, respectively, which is expected to be recognized over the nextone to three years. All stock-based compensation expense is recognized as a payroll-related expense and it is included within the general and administrative expenses line item within the Company’s income statement, and the offset is included in the additional paid-in capital line item of the Company’s balance sheet. At SeptemberOn June 30, 2021 2022 and 20202021, there were approximately 734,669780,167 and 177,876160,638 non-vested restricted shares issued and outstanding, respectively.

 

 

Note 5:  Fair Value

 

The Company carries various assetscash and liabilitiescash equivalents at fair value in the Condensed Consolidated Balance Sheets. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. ASC Topic 820 (“Fair Value Measurements”) establishes a three-tierthree-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

 

Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 - Include other inputs that are directly or indirectly observable in the marketplace.

Level 3 - Unobservable inputs which are supported by little or no market activity.

6

 

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. At SeptemberJune 30, 2021, 2022, the Company had invested virtually allthe majority of its $106.6$105.4 million cash and cash equivalents balance in money market funds which are classified within level 1.

 

 

Note 6:   Changes in Shareholders Equity

Changes in shareholders’ equity for the six months ended September 30, 2021 and 2020 are summarized below (in thousands):

      

Additional

     
  

Common

  

Paid-In

  

Retained

 
  

Stock

  

Capital

  

Earnings

 
             

Beginning balance at March 31, 2021:

 $20  $7,111  $134,141 

Share based compensation

  0   718   0 

Dividends declared

  0   0   (6,080)

Net income

  0   0   4,428 
             

Ending balance at June 30, 2021:

 $20  $7,829  $132,489 
             

Shares Issued

  1   0   0 

Share based compensation

  0   882   0 

Dividends declared

  0   0   (6,092)

Net income

  0   0   6,349 
             

Ending balance at September 30, 2021:

 $21  $8,711  $132,746 

7

Note 6:   Changes in Shareholders Equity (Continued)

      

Additional

     
  

Common

  

Paid-In

  

Retained

 
  

Stock

  

Capital

  

Earnings

 
             

Beginning balance at March 31, 2020:

 $20  $3,804  $126,177 

Share based compensation

  0   740   0 

Dividends declared

  0   0   (5,647)

Net income

  0   0   7,768 
             

Ending balance at June 30, 2020:

 $20  $4,544  $128,298 
             

Share based compensation

  0   773   0 

Dividends declared

  0   0   (5,647)

Net income

  0   0   8,412 
             

Ending balance at September 30, 2020:

 $20  $5,317  $131,063 

During the six months ended September 30, 2021 and 2020, there were 0 shares of common stock that were purchased or retired. At September 30, 2021, the Company had approximately $28.7 million remaining under the Company’s share repurchase plan.

Note 7:  Commitments and Contingencies

Legal Matters and Routine Proceedings

 

The Company has settled complaints that had been filed with various states’ pharmacy boards in the past. There can be no assurances made that other states will not attempt to take similar actions against the Company in the future. The Company initiates litigation to protect its trade or service marks. There can be no assurance that the Company will be successful in protecting its trade or service marks. Legal costs related to the above matters are expensed as incurred.

 

Employment AgreementNote 7:  Changes in Shareholders Equity:

 

On August 25,Changes in shareholders’ equity for the three months ended June 30, 2022 is summarized below (in thousands):

  

Additional

     
  

Paid-In

  

Retained

 
  

Capital

  

Earnings

 
         

Beginning balance at March 31, 2022:

 $11,660  $130,496 

Share based compensation

  1,536   0 

Dividends declared

  0   (6,297)

Net income

  0   2,775 
         

Ending balance at June 30, 2022:

 $13,196  $126,974 

Changes in shareholders’ equity for the three months ended June 30, 2021 Mathew N. Hulett was appointed as Chief Executive Officer and Presidentis summarized below (in thousands):

  

Additional

     
  

Paid-In

  

Retained

 
  

Capital

  

Earnings

 
         

Beginning balance at March 31, 2021:

 $7,111  $134,141 

Share based compensation

  718   0 

Dividends declared

  0   (6,080)

Net income

  0   4,428 
         

Ending balance at June 30, 2021:

 $7,829  $132,489 

There were no shares of common stock that were purchased or retired in the quarter ended June 30, 2022 or 2021. At June 30, 2022, the Company and as a member of the Board of Directors, and the Company entered into an employment agreement with Mr. Hulett to serve as the Company’s Chief Executive Officer and President, effective as of August 30, 2021. The employment agreement is for an initial term of three (3) years commencing on August 30, 2021 and will automatically renew for successive one (1) year terms, or for longer periods as mutually agreed upon by the parties, unless the employment agreement is expressly cancelled by either Mr. Hulett or the Company sixty (60) days prior to the end of the then current term, or is otherwise terminated as provided in the agreement. The employment agreement provides that Mr. Hulett will receive an annual base salary of $500,000, subject to periodic review for increases with the approval of the Board of Directors.

Mr. Hulett will be eligible to participate in the standard employee benefit plans generally available to executives and employees of the Company, including health insurance, life and disability insurance, restricted stockhad approximately $28.7 million remaining under the Company’s equity compensation plan(s), 401(k) plan, and paid time off and paid holidays. The Company will also reimburse Mr. Hulett for his documented business expenses incurred in connection with his employment pursuant to the Company's standard reimbursement expense policy and practices. The Company will not pay for any withholding taxes related to restricted stock compensation. The employment agreement contains certain rights of Mr. Hulett and the Company to terminate Mr. Hulett’s employment, including termination by the Company for “Cause” as defined in the employment agreement, and termination by Mr. Hulett for “Good Reason” as defined in the employment agreement within twelve (12) months of a Change in Control as defined in the employment agreement. Mr. Hulett is also entitled to severance pay equal to twelve (12) months of Mr. Hulett’s current base salary and eighteen (18) months of health insurance benefits in the event of his termination by the Company without Cause, or termination by Mr. Hulett for Good Reason within twelve (12) months of a Change in Control. The foregoing severance benefits are conditioned upon Mr. Hulett’s execution of a release of claims and compliance with certain restrictive covenants. The employment agreement contains customary non-disclosure and non-solicitation provisions as well as a one (1) year non-compete following the termination of the agreement.share repurchase plan.

8

On August 30, 2021, Mr. Hulett also received an award of 90,000 shares of restricted stock (“RSU”) under the Company’s 2016 Employee Plan, which stock restrictions will lapse pro rata on each of August 30, 2022, August 30, 2023 and August 30, 2024, which are subject to forfeiture in the event of termination of employment (except as provided in the RSU agreement). Mr. Hulett also received an award of 510,000 shares of performance restricted stock (“PSU”) under the 2016 Employee Plan, which stock restrictions will lapse on the third anniversary of the date of grant based on (i) achieving absolute stock price hurdles within the three-year period from the date of grant, and (ii) continued employment through the performance period of three years from the date of grant, in accordance with the following schedule:

Absolute Stock Price Hurdle

  

Shares

  

Cumulative Shares

 
$40   85,000   85,000 
$45   107,000   192,000 
$50   106,000   298,000 
$55   106,000   404,000 
$60   106,000   510,000 

Should none of the above absolute stock price hurdles be met during the three-year period from the date of grant no shares would vest. Once the absolute stock price hurdle is achieved, it will be considered to have met the absolute stock price hurdle, regardless of the stock price on the third anniversary of the date of grant. The absolute stock price hurdle would be considered to have been met if the average closing stock price of the Company is at or above the absolute stock price hurdle for a period of ninety (90) consecutive trading days. If the shares would be considered to have met the absolute stock price hurdle, they will only vest on the third anniversary of date of grant, subject to Mr. Hulett’s continued employment through the performance period of three years from the date of grant (except as provided in the PSU agreement).

In the event of Mr. Hulett’s termination of employment by the Company without Cause, or termination by Mr. Hulett for Good Reason within twelve (12) months of a Change in Control, or upon the executive’s Disability, Mr. Hulett would be entitled to the following:

(a)

a portion of the PSU award would vest to Mr. Hulett based on actual performance (absolute stock price hurdles) achieved up until the date of such termination; any PSU shares not having met the absolute stock price hurdles would be forfeited, and

(b)

the restrictions on the RSU award will lapse on a pro rata portion (number of days elapsed in vesting year/365) of the current year’s restricted stock (if not already lapsed) on the date of such event; any RSU shares related to the remainder of the current year’s restriction period, or to a future year’s restriction period, would be forfeited.

 

 

Note 8:  Income Taxes

 

For the quarters ended SeptemberJune 30, 2021 2022 and 2020,2021, the Company recorded an income tax provision of approximately $2.0$1.0 million and $2.5 million, respectively, and for the six months ended September 30, 2021 and 2020, respectively, the Company recorded an income tax provision of approximately $3.3 million and $4.5$1.4 million, respectively. The decrease into the income tax provision for the three and six monthsquarter ended SeptemberJune 30, 2021 2022 is related to a decrease in operating income during the periods.quarter. The effective tax rate for the quarter ended SeptemberJune 30, 2021 2022 was approximately 23.8%27.1%, compared to 22.6%approximately 23.5% for the quarter ended SeptemberJune 30, 2020, and the effective tax rate for the six months ended September 30, 2021 was approximately 23.7% compared to 21.7% for the six months ended September 30, 2020. 2021. The increase toin the effective tax rate for the quarter ended SeptemberJune 30, 2021 can be attributed2022 is due to more non-deductible expensesan increase in the September quarter.number of states that the Company has income tax nexus with, due to many of its employees working remotely in various states. The increase to the effective tax rate foris also related to an increase in stock compensation during the six months ended September 30, 2021 can be attributedquarter, which is expected to reverse during the Company receiving a one-time state incomefiscal year 2023 as the related compensation shares vest. The effective tax refund of $285,000rate should average out to approximately 24.5% in the June 2020 quarter.fiscal year 2023.

 

9
7

 

Note 9:  Related Party Transaction

 

The Company’s Board of Directors Chairman, Gian Fulgoni serves on the board of directors of Prophet, a brand and marketing consulting company, which the Company engaged with in March 2021 for $292,000. The Company expensed $32,000 in fiscal 2021 and $260,000 in fiscal the quarter ended June 30, 2021. There was 0 related expense in the quarter ended June 30, 2022. This transaction was approved by the Company’s Board of Directors with terms that are considered to be comparable to those with an unrelatedthird party.

 

 

Note 10:   Subsequent Events  Minority Interest Investment in Vetster

 

On April 19, 2022, the Company engaged in a October 25, 2021three-year ourpartnership agreement with Vetster Inc. (“Vetster”), a veterinary telehealth Canadian company. The Company also purchased a 5% minority interest in Vetster in the amount of $5.0 million and received warrants for additional equity in Vetster, which are tied to future performance milestones. Under the terms of the agreement, the Company becomes the exclusive e-commerce provider for Vetster, and Vetster becomes the exclusive provider of telehealth and telemedicine services to the Company. The minority interest investment is being valued on the cost basis and the investment will be evaluated periodically for any impairment. As of June 30, 2022, no revenue was recognized related to the Vetster partnership as the integration was not completed until after quarter end.

Note 11:  Subsequent Events

On July 14, 2022, the Board of Directors of Company appointed Christine Chambers to serve as the Company’s Chief Financial Officer and to assume the duties of principal financial officer and principal accounting officer effective August 3, 2022 (“Effective Date”). The Company entered into an offer letter with Ms. Chambers to set forth the terms and conditions of Ms. Chambers’ employment as Chief Financial Officer of the Company. Ms. Chambers will receive an annual base salary of $375,000 and will also receive a one-time sign-on bonus in the amount of $50,000, subject to pro-rata repayment if Ms. Chambers terminates employment with the Company within the first twelve months of employment. Ms. Chambers will receive an initial equity award under the 2016 Employee Plan consisting of (i) an award of 13,000 restricted shares, and (ii) 3,000 performance restricted shares, which performance restricted shares will be based on the attainment of performance criteria equally weighted between adjusted EBITDA and revenue. The shares for each grant will be released from restriction equally over a three (3) year period on the anniversary of the grant date, subject to the attainment of performance criteria in the case of the performance restricted shares.

The current Chief Financial Officer of the Company, Bruce Rosenbloom, will continue as the Company’s Chief Financial Officer until the Effective Date. The Company has presented a proposal to Mr. Rosenbloom regarding the continuation of his employment with the Company for services following the Effective Date until December 31, 2022. The Company and Mr. Rosenbloom are in the process of finalizing a transition and separation agreement with the Company.

On July 28, 2022, the Board of Directors declared a quarterly dividend of $0.30 per share. The Board of Directors established a November 8, 2021an August 12, 2022 record date and a Novemberan August 19, 20212022 payment date. Based on the outstanding share balance as of October 31, 2021 August 2, 2022 the Company estimates the dividend payable to be approximately $6.3 million.

 

On July 28, 2022, the Board of Directors approved and issued 39,215 restricted shares to certain employees of the Company, pursuant to the 2016 Employee Plan. The Board also approved the issuance of 37,500 restricted shares to the independent directors, pursuant to the 2015 Director Plan.

On August 1, 2022, the Board of Directors issued 13,000 restricted shares and 3,000 performance restricted shares to Christine Chambers, the Company’s new CFO, pursuant to the 2016 Employee Plan according to the terms of the offer letter. On August 1, 2022 the Board of Directors also approved and issued 7,000 shares to an employee of the Company, pursuant to the 2016 Employee Plan.

10


 

ITEM 2.   MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

Executive Summary

 

PetMed Express was incorporated in the state of Florida in January 1996. The Company’s common stock is traded on the NASDAQ Global Select Market under the symbol “PETS.”“PETS”. The Company began selling pet medications and other pet health products in September 1996. In March 2010 the Company started offering for sale additional pet supplies on its website, and these items are drop shipped to customers by third party vendors. Presently, the Company’s product line includes approximately 3,000 SKUs of the most popular pet medications, health products, and supplies for dogs, cats, and horses.

 

The Company markets its products through national advertising and promotional campaigns which aim to increase the recognition of the “PetMeds”“PetMeds®” brand name, increase traffic on its website at www.petmeds.com, acquire new customers, and maximize repeat purchases. Approximately 83%86% of all sales were generated via the Internet for both the quartersquarter ended SeptemberJune 30, 2021 and 2020.2022, compared to 84% for the quarter ended June 30, 2021. The Company’s sales consist of products sold mainly to retail consumers. The three-month average purchase was approximately $92 and $87 per order$95 for theboth quarters ended SeptemberJune 30, 20212022 and 2020, respectively, and the six-month average purchase was approximately $93 and $88 per order for the six months ended September 30, 2021, and 2020, respectively.

 

Critical Accounting Policies

 

Our discussion and analysis of our financial condition and the results of our operations contained herein are based upon our Condensed Consolidated Financial Statements and the data used to prepare them. The Company’s Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America. On an ongoing basis we re-evaluate our judgments and estimates including those related to product returns, bad debts, inventories, and income taxes. We base our estimates and judgments on our historical experience, knowledge of current conditions, and our beliefs of what could occur in the future considering available information. Actual results may differ from these estimates under different assumptions or conditions. Our estimates are guided by observing the following critical accounting policies.

 

Revenue recognition

 

The Company generates revenue by selling pet medication products and pet supplies mainly to retail customers. Certain pet supplies offered on the Company’s website are drop shipped to customers. The Company considers itself the principal in the arrangement because the Company controls the specified good before it is transferred to the customer. Revenue contracts contain one performance obligation, which is delivery of the product; customer care and support is deemed not to be a material right to the contract. The transaction price is adjusted at the date of sale for any applicable sales discounts and an estimate of product returns, which are estimated based on historical patterns, however itthis is not considered a key judgment. There are no amounts excluded from the variable consideration. Revenue is recognized when control transfers to the customer at the point in time in which the shipment of the product occurs. This key judgment is determined as the shipping point, which represents the point in time in whichwhere the Company has a present right to payment, title has transferred to the customer, and the customer has assumed the risks and rewards of ownership.

 

Outbound shipping and handling fees are an accounting policy election and are included in sales as the Company considers itself the principal in the arrangement given responsibility for supplier selection and discretion over pricing. Shipping costs associated with outbound freight after control over a product has transferred to a customer are an accounting policy election and are accounted for as fulfillment costs and are included in cost of sales. Virtually all of the Company’s sales are paid by credit cards and the Company usually receives the cash settlement in two to three banking days. Credit card sales minimize the accounts receivable balances relative to sales.

 

The Company maintains an allowance for doubtful accounts for losses that the Company estimates will arise from customers’ inability to make required payments, arising from either credit card charge-backschargebacks or insufficient funds checks. The Company determines its estimates of the un-collectability of accounts receivable by analyzing historical and current bad debts and current economic trends. The allowance for doubtful accounts was approximately $28,000$36,000 at SeptemberJune 30, 20212022, compared to $39,000 at March 31, 2021.2022.

 

119

 

Valuation of inventory

 

Inventories consist of prescription and non-prescription pet medications and pet supplies that are available for sale and are priced at the lower of cost or marketnet realizable value using a weighted average cost method. The Company writes down its inventory for estimated obsolescence. The inventory reserve was approximately $49,000$57,000 at SeptemberJune 30, 20212022 compared to $86,000$81,000 at March 31, 2021.2022.

 

Advertising

 

The Company's advertising expense consists primarily of Internet marketing, direct mail/print, and television advertising. Internet costs are expensed in the month incurred and direct mail/print advertising costs are expensed when the related brochures and postcards are produced, distributed, or superseded. Television advertising costs are expensed in the month advertisements are televised.

 

Accounting for income taxes

 

The Company accounts for income taxes under the provisions of ASC Topic 740 (“Accounting for Income Taxes”), which generally requires recognition of deferred tax assets and liabilities for the expected future tax benefits or consequences of events that have been included in the Company’s Condensed Consolidated Financial Statements or tax returns. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting carrying values and the tax bases of assets and liabilities and are measured by applying enacted tax rates and laws for the taxable years in which those differences are expected to reverse.

 

Results of Operations

 

The following should be read in conjunction with the Company’s Condensed Consolidated Financial Statements and the related notes thereto included elsewhere herein. The following table sets forth, as a percentage of sales, certain operating data appearing in the Company’s Condensed Consolidated Statements of Income:

 

 

Three Months Ended

 

Six Months Ended

  

Three Months Ended

 
 

September 30,

 

September 30,

  

June 30,

 
 

2021

  

2020

  

2021

  

2020

  

2022

  

2021

 
  

Sales

 100.0

%

 100.0

%

 100.0

%

 100.0

%

 100.0

%

 100.0

%

Cost of sales

 71.5  69.5  72.1  71.0  71.6  72.5 
              

Gross profit

  28.5   30.5   27.9   29.0   28.4   27.5 
  

Operating expenses:

  

General and administrative

 10.4  9.0  10.2  8.4  13.3  10.2 

Advertising

 5.1  6.8  7.6  8.3  9.0  9.7 

Depreciation

  1.0   0.8   0.9   0.7   1.1   0.8 

Total operating expenses

  16.5   16.6   18.7   17.4   23.4   20.7 
  

Income from operations

  12.0   13.9   9.2   11.6   5.0   6.8 
  

Total other income

  0.4   0.5   0.4   0.4   0.4   0.5 
  

Income before provision for income taxes

 12.4  14.4  9.6  12.0  5.4  7.3 
  

Provision for income taxes

  3.0   3.2   2.3   2.6   1.4   1.7 
  

Net income

  9.4

%

  11.2

%

  7.3

%

  9.4

%

  4.0

%

  5.6

%

 

12

Non-GAAP Financial Measures

Adjusted EBITDA and Adjusted EBITDA per share

To provide investors and the market with additional information regarding our financial results, we have disclosed (see below) adjusted EBITDA and adjusted EBITDA per share, non-GAAP financial measures that we calculate as net income excluding share-based compensation expense; depreciation and amortization; income tax provision; interest income (expense); and other expenses. We have provided reconciliations below of adjusted EBITDA to net income and adjusted EBITDA per share to diluted earnings per share, the most directly comparable GAAP financial measures.

We have included adjusted EBITDA and adjusted EBITDA per share, herein, because they are key measures used by our management and Board of Directors to evaluate our operating performance, generate future operating plans and make strategic decisions regarding the allocation of capital. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses. Accordingly, we believe that adjusted EBITDA and adjusted EBITDA per share provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and Board of Directors.

We believe it is useful to exclude non-cash charges, such as share-based compensation expense, depreciation and amortization from our adjusted EBITDA and adjusted EBITDA per share because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations. We believe it is useful to exclude income tax provision and interest income (expense), as neither are components of our core business operations. We also believe that it is useful to exclude other expenses, like the investment banking fee related to the Vetster partnership, which was executed in the June quarter, due to this expense being a one-time charge related to this specific transaction. Adjusted EBITDA and adjusted EBITDA per share have limitations as financial measures, these non-GAAP measures should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future and adjusted EBITDA and adjusted EBITDA per share do not reflect capital expenditure requirements for such replacements or for new capital expenditures;

Adjusted EBITDA and adjusted EBITDA per share do not reflect share-based compensation. Share-based compensation has been, and will continue to be for the foreseeable future, a material recurring expense in our business and an important part of our compensation strategy;

Adjusted EBITDA and adjusted EBITDA per share do not reflect interest income (expense), net; or changes in, or cash requirements for, our working capital;

Adjusted EBITDA and adjusted EBITDA per share do not reflect certain expenses like the investment banking fee related to the Vetster partnership, which was executed in the June quarter; and

Other companies, including companies in our industry, may calculate adjusted EBITDA and adjusted EBITDA per share differently, which reduces these measures’ usefulness as comparative measures.

Because of these and other limitations, adjusted EBITDA and adjusted EBITDA per share should only be considered as supplemental to, and alongside with other GAAP based financial performance measures, including various cash flow metrics, net income, net margin, and our other GAAP results.

11

The following table presents a reconciliation of net income, the most directly comparable GAAP measure to adjusted EBITDA and adjusted EBITDA per share for each of the periods indicated:

Reconciliation of Non-GAAP Measures

PetMed Express, Inc.

(Unaudited)

  

Three Months Ended

         
  

June 30,

  

June 30,

  $  

%

 

($ in thousands, except percentages)

 

2022

  

2021

  

Change

  

Change

 
                 

Consolidated Reconciliation of GAAP Net Income to Adjusted EBITDA:

 
                 

Net income

 $2,775  $4,428  $(1,653)  -37%
                 

Add (subtract):

                

Share-based compensation

 $1,536  $718  $818   114%

Income Taxes

 $1,030  $1,360  $(330)  -24%

Depreciation

 $753  $647  $106   16%

Interest Income/Expense

 $(117) $(85) $(32)  38%

Investment Banking Fee (Vetster)

 $355  $-  $355   - 
                 

Adjusted EBITDA

 $6,332  $7,068  $(736)  -10%

  

Three Months Ended

         

($ in thousands, except percentages

 

June 30,

  

June 30,

  

$

  

%

 

and per share amounts)

 

2022

  

2021

  

Change

  

Change

 
                 

Consolidated Reconciliation of GAAP Net Income Per Share to Adjusted EBITDA per share:

 
                 

Net income per share, diluted

 $0.14  $0.22  $(0.08)  -38%
                 

Add (subtract):

                

Share-based compensation

 $0.08  $0.04  $0.04   113%

Income Taxes

 $0.05  $0.07  $(0.02)  -25%

Depreciation

 $0.03  $0.03  $0.00   16%

Interest Income/Expense

 $(0.01) $(0.01) $(0.00)  37%

Investment Banking Fee (Vetster)

 $0.02  $-  $0.02   - 
                 

Adjusted EBITDA Per Share

 $0.31  $0.35  $(0.04)  -11%

12

 

Three Months Ended SeptemberJune 30, 20212022 Compared With Three Months Ended SeptemberJune 30, 2020, and Six Months Ended September 30, 2021 Compared With Six Months Ended September 30, 2020

 

COVID-19

 

We are dedicated to making every effort to ensure our customers’ pets receive the medications they need. We are also dedicated to making every effort to ensure the health and safety of our employees. We have continued with working from home where possible and enhanced disinfection and social distancing within our work place.workplace. The Company has been open during our normal business hours without any material disruptions to our operations. We have not seen any major disruptions in our supply chain,chain; however, we have experienced some delays in the delivery of some inventory items. See risk factorfactorsThe recent outbreak of the COVID-19 global pandemic and related government, private sector and individual consumer responsive actions may adversely affect our business operations, employee availability, financial performance, liquidity and cash flow for an unknown period of time and “Shipping is a critical part of our business and any changes in, or disruptions to, our shipping arrangements could adversely affect our business, financial condition, and results of operations in Part I, Item 1A of our Form 10-K for the year ended March 31, 2021.2022.

 

Sales

 

Sales decreased by approximately $8.1$9.1 million, or 10.7%11.5%, to approximately $67.4$70.2 million for the quarter ended SeptemberJune 30, 2021, from2022, compared to approximately $75.4$79.3 million for the quarter ended SeptemberJune 30, 2020. For the six months ended September 30, 2021, sales decreased by approximately $24.9 million, or 14.5%, to approximately $146.7 million compared to $171.6 million for the six months ended September 30, 2020.2021. The decrease in sales for the quarter and sixthree months ended SeptemberJune 30, 2021 was primarily due to decreased new ordersorder and reorder sales. Sales for the quarter and six months ended SeptemberJune 30, 20212022 were impacted by a much more competitive environment,slow start to flea/tick and a crowded advertising marketheartworm season which had substantially higher advertising costs compared tonegatively affected the same periods infirst half of the prior year. Veterinary visits increased during the quarter compared to being down during the prior year, due to the pandemic. We believe the increase in veterinary visits was primarily due to pet owners needing to visit their veterinarian for their pets’ annual exam in order to renew their prescriptions, as many veterinarians were closed due to the pandemic.quarter. The Company acquired approximately 65,00069,000 new customers for the quarter ended SeptemberJune 30, 2021,2022, utilizing the new 36-month definition of a new customer (described below), compared to approximately 96,00092,000 new customers for the quarter ended June 30, 2021. If we were using the same period36-month definition of a new customer in 2021, then the prior year. For the six months ended September 30, 2021 the Company acquired approximately 157,000 new customers, comparedcustomer would have increased to 282,000 new customers for the six months ended September 30, 2020.115,000. The following charttable illustrates sales by various sales classifications:

 

Three Months Ended September 30,

 

Sales (In thousands)

 

2021

  

%

  

2020

  

%

  

$ Variance

  

% Variance

 

Three Months Ended June 30,

Three Months Ended June 30,

 

Revenue (In thousands)

 

2022

  

%

  

2021

  

%

  

$ Variance

  

% Variance

 
  

Reorder Sales

 $62,016  92.0% $67,761  89.8% $(5,745) -8.5% $63,339  90.2% $70,937  89.4% $(7,598) -10.7%

New Order Sales

  5,370   8.0%  7,675   10.2%  (2,305)  -30.0%  6,848   9.8%  8,375   10.6%  (1,527)  -18.2%
  

Total Net Sales

 $67,386   100.0% $75,436   100.0% $(8,050)  -10.7% $70,187   100.0% $79,312   100.0% $(9,125)  -11.5%
  

Internet Sales

 $55,961  83.0% $62,697  83.1% $(6,736) -10.7% $60,295  85.9% $66,447  83.8% $(6,152) -9.3%

Contact Center Sales

  11,425   17.0%  12,739   16.9%  (1,314)  -10.3%  9,892   14.1%  12,865   16.2%  (2,973)  -23.1%
  

Total Net Sales

 $67,386   100.0% $75,436   100.0% $(8,050)  -10.7% $70,187   100.0% $79,312   100.0% $(9,125)  -11.5%

 

Six Months Ended September 30,

 

Sales (In thousands)

 

2021

  

%

  

2020

  

%

  

$ Variance

  

% Variance

 
                         

Reorder Sales

 $132,953   90.6% $148,186   86.3% $(15,233)  -10.3%

New Order Sales

  13,745   9.4%  23,454   13.7%  (9,709)  -41.4%
                         

Total Net Sales

 $146,698   100.0% $171,640   100.0% $(24,942)  -14.5%
                         

Internet Sales

 $122,408   83.4% $144,208   84.0% $(21,800)  -15.1%

Contact Center Sales

  24,290   16.6%  27,432   16.0%  (3,142)  -11.5%
                         

Total Net Sales

 $146,698   100.0% $171,640   100.0% $(24,942)  -14.5%

Please note that the Company changed the definition of a new customer on April 1, 2022, to include anyone who has not ordered over the past thirty-six months. The reorder and new order sales amounts for three months ended June 30, 2022 reflect this change in the new customer definition. The reorder and new order sales for the three months ended June 30, 2021 do not reflect this new customer definition change. Had the Company changed the definition of a new customer in the prior year, reorder sales would have been $68.7 million instead of $70.9 million reported above, and new order sales would have been $10.6 million instead of $8.4 million reported above.

In July 2021 we launched the new AutoShip & Save subscription program (“AutoShip”) on our website. AutoShip is a new convenient way for our loyal customer base to have future pet medication orders delivered directly to them without the need to place an order each time. During the quarter ended June 30, 2022 we made a change to the methodology on how we calculate the percentage of our revenue that was generated by our AutoShip program. Going forward, we will report AutoShip sales, net of discounts and credits, and we will also report the average of our AutoShip attainment over the quarter. This change to the calculation resulted in a decrease to the AutoShip percentage that was previously reported by only a few percentage points. We believe that this change reflects a more accurate representation of our subscription business for stakeholders to gauge its performance.

 

13

We are encouraged by the adoption of our AutoShip program and have seen an increasingly positive trend over the last several quarters since we launched this program. For example, our quarterly AutoShip percentage increased from 20% in the December quarter to 31% in the March quarter and averaged 34% for the most recent quarter ended June 30, 2022. The Company has set a goal of generating approximately 50% of its sales via the AutoShip program in FY 2023.

 

Going forward sales may be adversely affected due to increased competition and consumers giving more consideration to price. The changes in consumer behavior post pandemic makes future sales somewhat challenging to predict. No guarantees can be made that sales will grow in the future. The majority of our product sales are affected by the seasons, due to the seasonality of mainly heartworm, and flea and tick and heartworm medications. For the quarters ended June 30, September 30, December 31, and March 31 of Fiscal 2021,fiscal 2022, the Company’s sales were approximately 31%29%, 25%, 21%22%, and 23%24%, respectively, as a percentage of annual sales.

 

Cost of sales

 

Cost of sales decreased by approximately $4.2$7.3 million, or 8.0%12.7%, to approximately $48.2$50.2 million for the quarter ended SeptemberJune 30, 2021,2022, from approximately $52.4$57.5 million for the quarter ended SeptemberJune 30, 2020. For the six months ended September 30, 2021, cost of sales decreased by approximately $16.1 million, or 13.2%, to approximately $105.7 million compared to $121.8 million for the same period in the prior year.2021. The cost of sales decreasesdecrease can be directly related to the decreases todecrease in sales during the three and six monthsquarter ended SeptemberJune 30, 2021.2022. As a percentage of sales, cost of sales was 71.5%71.6% and 69.5%72.5% for the quarters ended SeptemberJune 30, 20212022 and 2020, respectively, and for the six months ended September 30, 2021, and 2020 cost of sales was 72.1% and 71.0%, respectively. The decrease in the cost of sales percentage for the quarter and six months were adversely impactedwas primarily due to the major manufacturers shifting their rebate funding from discounting product costs to cooperative marketing rebates.rebates to the reimbursement of promotion discounts which support the AutoShip subscription program.

 

Gross profit

 

Gross profit decreased by approximately $3.8$1.9 million, or 16.7%8.4%, to approximately $19.2$19.9 million for the quarter ended SeptemberJune 30, 2021,2022, from approximately $23.0$21.8 million for the quarter ended September 30, 2020. For the six months ended September 30, 2021 gross profit decreased by approximately $8.8 million, or 17.8%, to approximately $41.0 million, compared to $49.8 million for the same period in the prior year. The decrease in gross profit is directly related to a decrease in sales during the quarter and six months ended SeptemberJune 30, 2021. Gross profit as a percentage of sales was 28.5%28.4% and 30.5%27.5% for the three monthsquarters ended SeptemberJune 30, 20212022 and 2020, respectively, and for the six months ended September 30, 2021, and 2020, gross profit as a percentage of sales was 27.9% and 29.0%, respectively. The increase in the gross profit percentage decreases for the quarter and the six months can also be attributed to the major manufacturers shifting their rebate funding from discounting product costs to cooperative marketing rebates to the reimbursement of promotion discounts which support the AutoShip subscription program.

 

General and administrative expenses

 

General and administrative expenses increased by approximately $149,000,$1.4 million, or 2.2%16.3%, to approximately $6.9$9.4 million for the quarter ended SeptemberJune 30, 2021,2022, from approximately $6.8$8.0 million for the quarter ended SeptemberJune 30, 2020.2021. The increase into general and administrative expenses for the quarterthree months ended SeptemberJune 30, 20212022 was primarily due to the following: a $114,000 increase to other expenses, relating to increasing a state sales tax related accrual during the period; an $80,000$796,000 increase in professional fees;payroll expenses, the majority of which was related to stock compensation; and a $24,000 increase in travel related expenses, offset by a net decrease of $69,000 which included decreases in bank service fees and property expenses. For the six months ended September 30, 2021, general and administrative expenses increased by approximately $436,000, or 3.0%, to approximately $14.9 million, compared to $14.6 million for the same period the prior year. The increase in general and administrative expenses for the six months ended September 30, 2021 was primarily due to the following: a $418,000$464,000 increase in professional fees, with $260,000the majority of which was related to brand and marketing consultation; a $114,000 increase to other expenses, relating to increasing a state sales tax related accrual during the period; offset by a net decrease of $96,000 primarilyan investment banking fee related to a reduction in bank service fees due to a decrease in sales.the Vetster partnership and investment.

 

Advertising expenses

 

Advertising expenses decreased by approximately $1.7$1.4 million, or 33%17.3%, to approximately $3.4$6.3 million for the quarter ended SeptemberJune 30, 2021,2022, from approximately $5.1$7.7 million for the quarter ended SeptemberJune 30, 2020. For2021. Overall advertising spending for the six months ended September 30, 2021, advertising expensesquarter decreased by approximately $3.1 million, or 22%, to approximately $11.1 million compared to advertising expenses of approximately $14.2 million for the six months ended September 30, 2020. The decrease in advertising expenses forsame quarter the three months ended September 30, 2021 wasprior year, primarily due to management’s decision to reduce advertising spendthe delay of flea and tick season as a result of the colder weather in the quarter. During the quarter and six months ended September 30, 2021, while the pandemic was abating and many retail stores were re-opening, the advertising market was rapidly recovering with demand driving up advertising prices dramatically. As a result, our advertising for the three and six months ended September 30, 2021 was less effective in its ability to attract new customers.

14

month of April. The advertising costs of acquiring a new customer, defined as total advertising expensecosts divided by new customers acquired, was relatively flat, approximately $54$91 for the quartersquarter ended SeptemberJune 30, 2021 and 2020, and $712022 compared to $83 for the six monthsquarter ended SeptemberJune 30, 2021 compared to $50 for the six months ended September 30, 2020.2021. The increase for the six month ended September 30, 2021, was due to a substantialan increase in advertising prices.costs, compared to the same quarter in the prior year. The advertising cost of acquiring a new customer can be impacted by the advertising environment, the effectiveness of our advertising creative, advertising spending, and price competition. Historically, the advertising environment fluctuates due to supply and demand. A more favorable advertising environment may positively impact future new order sales, whereas a less favorable advertising environment may negatively impact future new order sales. As a percentage of sales, advertising expense was 5.1%9.1% and 6.8%9.7% for the quarters ended SeptemberJune 30, 20212022 and 2020, and for the six months ended September 30, 2021, and 2020 advertising expense was 7.6% and 8.3%, respectively. The decrease in advertising expense as a percentage of total sales for the three and six monthsquarter ended SeptemberJune 30, 20212022 can be mainly attributed to decreased salesthe slow start to flea/tick and aheartworm season which affected the first half of the quarter, which negatively impacted sales. In response to the reduction in sales the Company reduced advertising expense.spend in the quarter compared to the quarter ended June 30, 2021. The advertising percentage will fluctuate quarter to quarter due to seasonality and advertising availability, and return on investment requirements.availability.

14

 

Depreciation

 

Depreciation expense increased by approximately $87,000 to approximately $694,000was $753,000 and $647,000 for the quarterquarters ended SeptemberJune 30, 2022 and 2021, from approximately $607,000 for the quarter ended September 30, 2020. For the six months ended September 30, 2021 and 2020 depreciation expense was approximately $1.3 and $1.2 million, respectively. TheThis increase to depreciation expense for the quarter and six months ended SeptemberJune 30, 20212022 can be attributed to new property and equipment additions during the same periods.quarter.

 

Other income

 

Other income decreased by approximately $160,000 to approximately $244,000$315,000 for the quarter ended SeptemberJune 30, 2021 from2022 compared to approximately $404,000$369,000 for the quarter ended SeptemberJune 30, 2020. For the six months ended September 30, 2021 other income decreased by approximately $136,000 to approximately $613,000 compared to approximately $749,000 for the same period in the prior year.2021. The decrease to other income for the quarter and six months ended SeptemberJune 30, 20212022 is primarily related to decrease ina reduction to advertising income. Interest income may decrease in the future as the Company utilizes its cash balances on any quarterly dividend payment, on future investments or partnerships, on its operating activities, or on its share repurchase plan, with approximately $28.7 million remaining as of SeptemberJune 30, 2021, on any quarterly dividend payment or on its operating activities.2022.

 

Provision for income taxes

 

For the quarters ended SeptemberJune 30, 20212022 and 2020,2021, the Company recorded an income tax provision of approximately $2.0$1.0 million and $2.5 million, respectively, and for the six months ended September 30, 2021 and 2020, the Company recorded an income tax provision of approximately $3.3 million and $4.5$1.4 million, respectively. The decrease into the income tax provision for the three and six monthsquarter ended SeptemberJune 30, 20212022 is related to a decrease in operating income during the periods.quarter. The effective tax rate for the quarter ended SeptemberJune 30, 20212022 was approximately 23.8%27.1%, compared to 22.6%approximately 23.5% for the quarter ended SeptemberJune 30, 2020, and the effective tax rate for the six months ended September 30, 2021 was approximately 23.7% compared to 21.7% for the six months ended September 30, 2020.2021. The increase toin the effective tax rate for the quarter ended SeptemberJune 30, 2021 can be attributed2022 is due to more non-deductible expensesan increase in the September quarter.number of states that the Company has income tax nexus with, due to many of its employees working remotely in various states. The increase to the effective tax rate foris also related to an increase in stock compensation during the six months ended September 30, 2021 can be attributedquarter, which is expected to reverse during the Company receiving a one-time state incomefiscal year 2023 as the related compensation shares vest. The effective tax refund of $285,000rate should average out to approximately 24.5% in the June 2020 quarter.fiscal year 2023.

 

Liquidity and Capital Resources

 

The Company’s working capital at SeptemberJune 30, 20212022 and March 31, 20212022 was $117.2$110.3 million and $116.3$117.8 million, respectively. The approximately $900,000 increase$7.5 million decrease in working capital was primarily attributable to income generated by operations and a reductiondecrease in cash to accounts payable, offset by dividends paidfund the investment in the period.Vetster partnership. Net cash provided by operating activities was $1.1 million and $15.2$6.4 million for the sixthree months ended SeptemberJune 30, 2021 and 2020, respectively.2022, compared to cash used in operating activities of $422,000 for the three months ended June 30, 2021. This change is primarily due to a greater reduction in net income and a decrease in accounts payable and inventory than in the prior year, offset by a decrease in inventories.to net income. Net cash used in investing activities was $972,000$6.0 million for the sixthree months ended SeptemberJune 30, 2021,2022, compared to net cash$477,000 used in investing activities of $1.2 million for the sixthree months ended SeptemberJune 30, 2020.2021. This change in investing activities is related to an increasethe investment in the Vetster partnership and increased property and equipment additions acquired in the six months ended September 30, 2021.quarter. Net cash used in financing activities was $12.3$6.1 million for the six monthsquarter ended SeptemberJune 30, 2021,2022 compared to $11.4$6.0 million for the same period in the prior year. The change to financing activities relates to an increase in the dividend paid in the six monthsquarter ended SeptemberJune 30, 2021, compareddue to the prior period. At Septemberdeclaration of the $0.30 per share dividend during the quarters ended June 30, 2022, and 2021, respectively.

As of June 30, 2022, the Company had approximately $28.7 million remaining under the Company’s share repurchase plan.

15

Subsequent to September 30, 2021, on October On July 25, 20212022 our Board of Directors declared a $0.30 per share dividend. The Board of Directors established a November 8, 2021an August 12, 2022 record date and a Novemberan August 19, 20212022 payment date.date for the quarterly dividend. Depending on future market conditions the Company may utilize its cash and cash equivalents on quarterly dividends, on its operating activities, or on the remaining balance of its current share repurchase plan, on dividends, or on its operating activities.plan.

 

At SeptemberAs of June 30, 2021,2022, the Company had no material outstanding lease commitments. We are not currently bound by any long- or short-term agreements for the purchase or lease of capital expenditures. Any material amounts expended for capital expenditures would be the result of an increase in the capacity needed to adequately provide for any increase in our business. To date we have paid for any needed additions to our capital equipment infrastructure from working capital funds and anticipate this being the case in the future. Presently, we have approximately $1.0$4.0 million forecasted for capital expenditures for the remainder of fiscal 2022,2023, the majority of which will be invested in our e-commerce platform and IT infrastructure to better service our customers, which willand are expected to be funded through cash from operations. The Company’s primary source of working capital is cash from operations. The Company presently has no need for alternative sources of working capital and has no commitments or plans to obtain additional capital.

 

Off-Balance Sheet Arrangements

The Company had no off-balance sheet arrangements at September 30, 2021.

15

 

Cautionary Statement Regarding Forward-Looking Information

 

Certain information in this Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these forward-looking statements by the words "believes," "intends," "expects," "may," "will," "should," "plans," "projects," "contemplates," "intends," "budgets," "predicts," "estimates," "anticipates," or similar expressions. These statements are based on our beliefs, as well as assumptions we have used based upon information currently available to us. Because these statements reflect our current views concerning future events, these statements involve risks, uncertainties, and assumptions. Actual future results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed in Part I, Item 1A of the Company’s Annual Report on Form 10-K for the year ended March 31, 2022 under the heading “Risk Factors.” A reader, whether investing in our common stock or not, should not place undue reliance on these forward-looking statements, which apply only as of the date of this quarterly report. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law. When used in this quarterly report on Form 10-Q, "PetMed Express," "1-800-PetMeds," "PetMeds," "PetMed," "PetMeds.com," “1800PetMeds.com,” "PetMed.com," "PetMed Express.com," "the Company," "we," "our," and "us" refers to PetMed Express, Inc. and our subsidiaries.

ITEM 3.

ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

Market risk generally represents the risk that losses may occur in the value of financial instruments as a result of movements in interest rates, foreign currency exchange rates, and commodity prices. Our financial instruments include cash and cash equivalents, accounts receivable, and accounts payable. The book values of cash and cash equivalents, accounts receivable, and accounts payable are considered to be representative of fair value because of the short maturity of these instruments. Interest rates affect our return on excess cash and cash equivalents. At SeptemberJune 30, 2021,2022, we had $106.6$105.4 million in cash and cash equivalents, and the majority of our cash and cash equivalents generate interest income based on prevailing interest rates. A significant change in interest rates would impact the amount of interest income generated from our excess cash and cash equivalents. It would also impact the market value of our cash and cash equivalents. Our cash and cash equivalents are subject to market risk, primarily interest rate and credit risk. Our cash and cash equivalents are managed by a limited number of outside professional managers within investment guidelines set by our Board of Directors. Such guidelines include security type, credit quality, and maturity, and are intended to limit market risk by restricting our cash and cash equivalents to high-quality cash and cash equivalents with both short- and long-term maturities. We do not hold any derivative financial instruments that could expose us to significant market risk. At SeptemberJune 30, 2021,2022, we had no debt obligations.

 

16

ITEM 4.

ITEM 4.  CONTROLS AND PROCEDURES.

 

Evaluation of Disclosure Controls and Procedures

 

The Company’s management, including our Chief Executive Officer and Chief Financial Officer, has conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a‑15 promulgated under the Securities Exchange Act of 1934, as amended) as of the quarter ended SeptemberJune 30, 2021,2022, the end of the period covered by this report (the "Evaluation Date"). Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded as of the Evaluation Date, that our disclosure controls and procedures are effective such that the information relating to our Company, including our consolidated subsidiaries, required to be disclosed by the Company in reports that it files or submits under the Exchange Act: (1) is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and (2) is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting during our most recently completed fiscal quarter that hashave materially affected, or isare reasonably likely to materially affect, our internal control over financial reporting.

 

16

PART II - OTHER INFORMATION

ITEM 1.

ITEM 1.  LEGAL PROCEEDINGS.

 

None.

 

ITEM1A.  RISK FACTORS.

RISK FACTORS.

 

Our operations and financial results are subject to various risks and uncertainties that could adversely affect our business, financial condition, results of operations, and trading price of our common stock. Please refer to our Annual Report on Form 10-K for Fiscal Year 2021fiscal 2022 for additional information concerning these and other uncertainties that could negatively impact the Company.

ITEM 2.

ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

The Company did not make any sales of unregistered securities during the secondfirst quarter of Fiscal 2022.fiscal 2023.

 

Issuer Purchases of Equity Securities

 

None.

ITEM 3.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES.

 

None.

ITEM 4.

ITEM 4.  MINE SAFETY DISCLOSURES.

 

Not applicable.

ITEM 5.

ITEM 5.  OTHER INFORMATION.

 

None.

 

17

ITEM 6.EXHIBITS

EXHIBITS

 

The following exhibits are filed as part of this report.

 

31.1

Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, promulgated under the Securities Exchange Act of 1934, as amended (filed herewith to Exhibit 31.1 of the Registrant’s Report on Form 10-Q for the quarter ended SeptemberJune 30, 2021,2022, Commission File No. 000-28827).

 

31.2

Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, promulgated under the Securities Exchange Act of 1934, as amended (filed herewith to Exhibit 31.2 of the Registrant’s Report on Form 10-Q for the quarter ended SeptemberJune 30, 2021,2022, Commission File No. 000-28827).

 

32.1

Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith to Exhibit 32.1 of the Registrant’s Report on Form 10-Q for the quarter ended SeptemberJune 30, 2021,2022, Commission File No. 000-28827).

 

101.INS*

Inline XBRL Instance Document (the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)

101.SCH*

Inline XBRL Taxonomy Extension Schema Document

101.CAL*

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE*

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

   *

*XBRL information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

17

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

PETMED EXPRESS, INC.

(The “Registrant”)

Date: August 2, 2022

By:

  /s/ Mathew N. Hulett

 

(The “Registrant”)

Date: November 2, 2021

By:

/s/   Mathew N. Hulett  

Mathew N. Hulett

 
   

Chief Executive Officer and President

 

(principal executive officer)

 
   

By:

/s/  /s/ Bruce S. Rosenbloom

 

Bruce S. Rosenbloom

 
   

Chief Financial Officer

 

 

(principal financial and accounting officer)

 

 

18

 



 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C.20549D.C. 20549

 

 

_______________________

 

 

 

PETMED EXPRESS, INC

 

 

_______________________

 

 

 

FORM 10-Q

 

 

FOR THE QUARTER ENDED:

 

SEPTEMBERJUNE 30, 20212022

 

 

_______________________

 

 

EXHIBITS

 

_______________________